Natalizumab is a second-line treatment for multiple sclerosis.
It acts by binding to α4β1-integrin and blocks its interaction with VCAM-1. This results in inhibition of leukocyte migration into the central nervous system.
It is administered through intravenous infusion every month.
In 2016, it sold €347 million in Europe.
It has an immunogenicity rate of 6-9%.
Labs that test for drug level:
Labs that test for ADA titre: